GSK plc announced statistically significant and clinically meaningful overall survival (OS) results from Part 1 and progression-free survival (PFS) results from Part ...
GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial. The results ...
GSK has said that a regimen of PD-1 inhibitor Jemperli with PARP inhibitor Zejula has shown efficacy in the second stage of the RUBY trial, which could open up wider use in endometrial cancer. RUBY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results